DL-AP7 is a competitive antagonist of the ionotropic glutamate receptor, NMDA. Studies indicate that the S1 and S2 domains of the NMDA receptor are essential in DL-AP7 and other related antagonists to bind to the receptor. In addition, the positively charged Lys residues at the second interaction site and Arg at the fourth site are key factors in ligand binding. The NMDA receptor is unique in that it requires binding of two ligands, glutamate and glycine to become activated. As a result of its inhibitory affects, DL-AP7 is an ideal tool in studying signaling pathways and ion flow through the NMDA receptor.
1. Laube, B., et al. 1997. Neuron. 18: 493-503. PMID: 9115742
2. Liu, Y. and Zhang, J. 2000. Chin. Med. J. 113: 948-956. PMID: 11775847
3. Blaise, M.C., et al. 2005. J Mol Model. 11: 489-502. PMID: 15928921
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.